ERBB2 and breast cancer: In the neoadjuvant setting, 83% and 71% of HER2-positive patients (luminal and non-luminal, respectively) were treated by a dual HER2 blockade consisting of trastuzumab and pertuzumab, while the others received only trastuzumab (except for one patient with breast cancer during pregnancy).